Novartis, at work on a cardio drug widely expected to bring in billions of dollars once approved, is working to tamp down concerns that the oral treatment could increase the risk of Alzheimer's disease, adding measures of brain function to an ongoing trial.
Months after a bitter exit from the top spot at Sanofi, Christopher Viehbacher is back out in public, joining Boston startup factory PureTech to help steer its portfolio of fledgling companies.
Pushing through on a plan to get out of the early-stage anti-infectives R&D space, AstraZeneca is spinning out its Waltham, MA-based company into an independent biotech, a move that will have an impact on the 95 staffers remaining in the swiftly dwindling operation.
South San Francisco's Lyric Pharmaceuticals raised $20.4 million in first-round financing to support its work on a hush-hush gastrointestinal drug.
A fast-changing Merck KGaA is backing away from discovery and preclinical R&D deals it set up with the antibody specialists at Ablynx. And the Belgian biotech saw its shares slide 14% today after news of the prospective breakup--included in Ablynx's annual summary--spread in the markets.
Exact Sciences is charting big plans for 2015, increasing its sales efforts and pushing for expanded coverage of its stool-based DNA colon cancer test to grab a bigger market share.
Entrepreneur Keith Kocho is designing a smart tablet specifically for the elderly. He's been given $1 million from Google Ventures and Atlas Venture to work on the project.
Valeant only just picked up Provenge from bankrupt Dendreon, but it's already trumpeting positive data for the flailing prostate cancer vaccine.
Illumina has revealed a new fund structure to back startup graduates from its accelerator that launched early last year. Dubbed Illumina Accelerator Boost Capital, the fund has secured an initial $40 million capital commitment from Viking Global Investors.
Prexton Therapeutics, the first company to emerge from the €30 million ($34 million) biotech-creation program Merck Serono set up amid the shuttering of its Geneva R&D center, has closed a Series A round.